<DOC>
	<DOCNO>NCT02200354</DOCNO>
	<brief_summary>For patient nonsquamous NSCLC good performance status ( PS ) , pemetrexed cisplatin recommend first-line NSCLC treatment . Recently , result PARAMOUNT trial show patient nonsquamous NSCLC good PS progress complete four cycle pemetrexed-cisplatin induction therapy benefit pemetrexed continuation maintenance therapy . Furthermore , pemetrexed bevacizumab continuous maintenance might better treatment option , consider result AVAPEARL trial . Pemetrexed rechallenge report effective patient . Therefore , order investigate safety efficacy pemetrexed rechallenge bevacizumab , conduct study .</brief_summary>
	<brief_title>The Safety Efficacy Pemetrexed Rechallenge With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>20 Years old PS02 Advanced nonsquamous nonsmall cell lung cancer ; AND Patients receive 4 cycle pemetrexed therapy study Interstitial pneumonia ; AND Abnormal blood test</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>